Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL
The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.
Aggressive Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma
DRUG: Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
The primary endpoint is to evaluate Overall response rate (ORR), The primary endpoint is to evaluate the number of patients with complete remission, unconfirmed complete remission and partial response according to International Workshop to Standardize Response Criteria for NHL, of R-GEMOX combination administered every 14 days, 3 years and 2 months
Safety of Gemcitabine in combination with Rituximab, Oxaliplatin and Dexametasone (R-GemOx) in DLBCL and Mantle cell lymphoma. (GELTAMO-RGemOx), To asses the number of Participants with Adverse Events (serious and non serious) and classification of those adverse events.

Evaluate if the balance efficacy / toxicity allows the possibility of further interventions to prolong progression-free survival and overall survival, 3 years and 2 months|To identify clinical response predictive factors, To asses if different age, sex, IPI, ECOG, stage of cancer, dissease location and time to relapse have some influence in response., 3 years 2 months
The purpose of this study is to determine efficacy (overall response rate (ORR) and complete response) tolerance and toxicity of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.